Andrew Weiss News
-
Actelion Ltd. said earnings will remain stable in 2013 before rising in 2014 and accelerating to “double-digit” growth in 2015 as a new blood pressure drug spurs sales.
-
Actelion Ltd.’s experimental lung drug macitentan met the main goal of a late-stage clinical trial, giving the company a possible successor to a treatment that accounts for 89 percent of sales. The shares rose the most since the company went public in 2000.
-
Malcolm has $30 billion, a passion for steaks, and a plan to buy 3 billion steaks for $10 each on his next birthday.
-
Illumina Inc., the U.S. maker of gene-mapping tools, rose above Roche Holding AG’s increased hostile takeover bid, indicating investors are betting that an even higher offer will come.
-
Roche Holding AG delayed development of the experimental diabetes drug taspoglutide by at least 12 to 18 months after more people than expected suffered from side effects such as skin reactions and digestive symptoms.
-
Novartis AG said that an experimental antibody relieved pain and stopped new attacks of gout better than a steroid injection in two advanced studies.
-
Roche Holding AG’s failure to persuade a U.S. panel to back Avastin in breast cancer is the third such loss for the Swiss drugmaker as it looks for new ways to expand sales of the world’s top-selling cancer medicine.
-
Novartis AG indicated Alcon Inc. shareholders should take another look at its $11.5 billion buyout offer now that an increase in the Swiss drugmaker’s share price and a rally in the franc have lifted the value of the bid.
-
Roche Holding AG agreed to buy Anadys Pharmaceuticals Inc. for about $230 million to build its portfolio of experimental drugs for hepatitis C, a market that may be worth as much as $15 billion annually by 2019.
-
Novartis AG’s kidney-cancer drug Afinitor also prevented breast cancer from worsening in a study that the Swiss drugmaker plans to use in applying for regulatory approval.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page